The Effect of Eplerenone on Ischemia Reperfusion Injury in Human Myocardium (EPLICARD Study)

Trial Profile

The Effect of Eplerenone on Ischemia Reperfusion Injury in Human Myocardium (EPLICARD Study)

Active, no longer recruiting
Phase of Trial: Phase II

Latest Information Update: 29 Jan 2016

At a glance

  • Drugs Eplerenone (Primary) ; Aldosterone
  • Indications Reperfusion injury
  • Focus Therapeutic Use
  • Acronyms EPLICARD
  • Most Recent Events

    • 29 Jan 2016 Last checked against ClinicalTrials.gov record.
    • 11 Jan 2016 No of arms changed from 4 to 2 in which patients exposed to Caffeine and aldosterone are removed as per ClinicalTrials.gov record.
    • 11 Jan 2016 Status changed from recruiting to active, no longer recruiting as per ClinicalTrials.gov record.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top